StreetInsider.com News Articles

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical^® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.

H.C. Wainwright Conference Presentation Details:
Presentation Date: Tuesday, September 15, 2026
Presentation Time: 2:00 PM ET
Location: Kennedy II Room, Lotte New York Palace Hotel, New York, NY
Webcast Link: https://ir.envoymedical.com/news-events/ir-calendar

To schedule a one-on-one

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

To schedule a one-on-one

Form 8-K Envoy Medical, Inc. For: Aug 24

Thu, 27 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26991399.html

Form 8-K Envoy Medical, Inc. For: Aug 24

Thu, 27 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26991399.html

Form 4 Envoy Medical, Inc. For: Aug 24 Filed by: Potashnick Robert

Wed, 26 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260826/26982752.html

Form 4 Envoy Medical, Inc. For: Aug 24 Filed by: Potashnick Robert

Wed, 26 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260826/26982752.html

Envoy Medical (COCH) PT Lowered to $2 at H.C. Wainwright

Fri, 21 Aug 2026 07:02:57 -0400

(Updated - August 21, 2026 7:02 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Envoy Medical (NASDAQ: COCH) to $2.00 (from $2.50) while maintaining a Buy rating.

The analyst commented: "Envoy Medical recently reported its 2Q26 financial results. Revenue was $51K. Net loss was $7.3M, or ($0.07) per share, slightly higher than our estimated loss of $6.6M. Importantly, the company submitted the first of four planned modules of a modular premarket approval (PMA) application to the FDA for the Acclaim cochlear implant in June 2026, with the final clinical module targeted for submission in 2Q27. In July, the

Envoy Medical (COCH) PT Lowered to $2 at H.C. Wainwright

Fri, 21 Aug 2026 07:02:57 -0400

(Updated - August 21, 2026 7:02 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Envoy Medical (NASDAQ: COCH) to $2.00 (from $2.50) while maintaining a Buy rating.

Form PRE 14A Envoy Medical, Inc. For: Aug 19

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950504.html

Form PRE 14A Envoy Medical, Inc. For: Aug 19

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950504.html

New to The Street Airs This Weekend Across Bloomberg Television U.S., Latin America and MENA

Sat, 15 Aug 2026 10:40:00 -0400

Envoy Medical, Sagtec Global, RHINO Bitcoin and Virtuix Holdings Featured in This Weekend's Global Broadcast